Molecular targeted therapies for cancer: Sorafenib mono­therapy and its combination with other therapies (Review)

  • Authors:
    • Nuha Ibrahim
    • Yan Yu
    • William R. Walsh
    • Jia-Lin Yang
  • View Affiliations

  • Published online on: February 6, 2012     https://doi.org/10.3892/or.2012.1675
  • Pages: 1303-1311
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sorafenib is an oral multikinase inhibitor that acts by inhibiting tumor growth and disrupting tumor microvasculature through antiproliferative, anti-angiogenic and proapoptotic effects. It exerts these effects via inhibition of multiple targets including Raf serine/threonine kinases, vascular endothelial growth factor receptor tyrosine kinases; VEGFR-1, VEGFR-2, VEGFR-3 and platelet-derived growth factor receptor β (PDGFR-β). Current literature shows that the deregulated signaling through these receptors is commonly seen in human tumors. In addition, sorafenib is also shown to induce apoptosis through downregulation of Mcl-1 in many cancer types. Hence, sorafenib as a single agent has shown promising activity in some cancers such as renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and thyroid cancers. Currently, the drug holds FDA approval for the treatment of advanced RCC and unresectable HCC. However, many clinical studies have indicated several limitations to the application of sorafenib as a single agent in various other cancers. Owing to these reasons and the potential of sorafenib to synergize with other anticancer therapies, its combination with other targeted agents and chemotherapy has been widely explored with promising results. In addition, it has also shown synergistic results when combined with radiation. This review summarizes the current basic and clinical studies on the effects and mechanisms of sorafenib either administered alone or in combination with other anticancer treatments.

Related Articles

Journal Cover

May 2012
Volume 27 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ibrahim N, Yu Y, Walsh WR and Yang J: Molecular targeted therapies for cancer: Sorafenib mono­therapy and its combination with other therapies (Review) . Oncol Rep 27: 1303-1311, 2012.
APA
Ibrahim, N., Yu, Y., Walsh, W.R., & Yang, J. (2012). Molecular targeted therapies for cancer: Sorafenib mono­therapy and its combination with other therapies (Review) . Oncology Reports, 27, 1303-1311. https://doi.org/10.3892/or.2012.1675
MLA
Ibrahim, N., Yu, Y., Walsh, W. R., Yang, J."Molecular targeted therapies for cancer: Sorafenib mono­therapy and its combination with other therapies (Review) ". Oncology Reports 27.5 (2012): 1303-1311.
Chicago
Ibrahim, N., Yu, Y., Walsh, W. R., Yang, J."Molecular targeted therapies for cancer: Sorafenib mono­therapy and its combination with other therapies (Review) ". Oncology Reports 27, no. 5 (2012): 1303-1311. https://doi.org/10.3892/or.2012.1675